Get the Stockscreener App
3.60
6.51%
0.22
After Hours:
3.76
0.16
+4.44%
Erasca Inc stock is traded at $3.60, with a volume of 1.77M.
It is up +6.51% in the last 24 hours and up +35.85% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$3.38
Open:
$3.4
24h Volume:
1.77M
Relative Volume:
0.97
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-4.3902
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+10.09%
1M Performance:
+35.85%
6M Performance:
+135.29%
1Y Performance:
+36.88%
1-Day Range:
$3.37
$3.62
1-Week Range:
$3.15
$3.62
52-Week Range:
$1.01
$3.62
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
3.60 | 958.95M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks - simplywall.st
Aug Breakouts: Is Erasca Inc stock a buy for dividend growthEarnings Growth Report & AI Optimized Trading Strategy Guides - moha.gov.vn
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Mizuho Maintains Erasca (ERAS) Outperform Recommendation - Nasdaq
Check Out Erasca Inc (ERAS)’s Trade Data Rather Than the Analysts’ Views - Setenews
Mizuho raises Erasca stock price target to $5 on RAS space optimism - Investing.com Canada
Erasca price target raised to $5 from $4 at Mizuho - TipRanks
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Hold" by Analysts - MarketBeat
Affinity Asset Advisors LLC Grows Stock Holdings in Erasca, Inc. $ERAS - Defense World
Will Erasca Inc. stock outperform international peers2025 Top Gainers & Fast Gaining Stock Reports - Newser
Gitlab, Acadia Healthcare, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results - Insider Monkey
Moving Averages: Why Erasca Inc. stock could be next big winnerInsider Buying & Momentum Based Trading Signals - moha.gov.vn
Unusually active option classes on open October 8th - MSN
Erasca to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
Adversity is less terrifying than hope: Erasca Inc (ERAS) - Setenews
Understanding Erasca Inc.’s price movementPortfolio Risk Summary & High Yield Equity Trading Tips - newser.com
Will Erasca Inc. stock benefit from automation2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Erasca Inc. stock chart pattern explainedJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Erasca Inc. stock remains on watchlistsWeekly Stock Analysis & Free Weekly Watchlist of Top Performers - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
ErascaTargeting Cancer's Most Commonly Mutated Pathway - RTTNews
Analyzing Precision BioSciences (NASDAQ:DTIL) and Erasca (NASDAQ:ERAS) - Defense World
HC Wainwright Issues Optimistic Estimate for Erasca Earnings - Defense World
Heatmap analysis for Erasca Inc. and competitorsEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Analyzing net buyer seller activity in Erasca Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Using fundamentals and technicals on Erasca Inc.IPO Watch & Risk Managed Investment Signals - newser.com
HC Wainwright Comments on Erasca’s Q1 Earnings (NASDAQ:ERAS) - Defense World
Why Erasca Inc. stock could see breakout soonTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Is Erasca Inc. stock poised for growthQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Erasca, Inc. Reports Q3 2025 Financial Results - MSN
Guggenheim raises Erasca stock price target to $5 on pipeline progress By Investing.com - Investing.com South Africa
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):